Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Suspended 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 22Sarcoma 2Genitourinary 2CNS 2Thoracic 1Other solid neoplasm 1Lymphoid 1Head & Neck 1

Conditions

Urinary Bladder Neoplasms 1Advanced Renal Cell Carcinoma 1

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 151Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × balstilimab × Genitourinary × Clear all
NCT05928806 2026-02-11

ARCITECT

Hoosier Cancer Research Network

Phase 2 Suspended
120 enrolled
Genitourinary

Advanced Renal Cell Carcinoma

NCT04430036 2024-04-04

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

The University of Texas Health Science Center at San Antonio

Phase 2 Terminated
4 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡